ASX Announcement

15 May 2026

OSPREY Registry Interim Results Presented at ESGE Days 2026

Highlights

- Interim OSPREY Registry results presented at ESGE (European Society of Gastrointestinal Endoscopy) Days 2026 demonstrating encouraging real-world safety and efficacy outcomes for OncoSil™ in patients with unresectable locally advanced pancreatic cancer (LAPC)
- OSPREY Registry enrolment exceeded 80 patients, with interim analysis based on 64 patients enrolled across Austria, Greece, Italy and Spain
- Strong safety profile observed, with no Grade ≥3 adverse device effects (ADEs) and no serious adverse device effects (SADEs) reported
- Local Disease Control Rate at 12 weeks post-implant was 91.4% in first-line chemotherapy patients and 77.8% in second-line chemotherapy patients
- Seven patients underwent surgical resection with curative intent following OncoSil™ treatment, with 71.4% achieving R0 resection margins (complete microscopic removal of the tumour)
- Median overall survival was 20.6 months in first-line chemotherapy patients implanted within ≤4 months of commencing chemotherapy, and 22.0 months in those implanted between 4–12 months.

Sydney, Australia – 15 May 2026: OncoSil Medical Limited (ASX: OSL) ("OncoSil Medical" or "the Company"), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce that interim results from the ongoing OSPREY Registry were presented at ESGE Days 2026, highlighting encouraging safety and efficacy outcomes for patients with unresectable LAPC treated with OncoSil™ in routine clinical practice. This initial data was previously announced to ASX on 3 December 2025.

The presentation, titled "*OSPREY Registry: First Interim Analysis of Patients with Unresectable Locally Advanced Pancreatic Cancer Treated with EUS-Guided Phosphorus-32 Microparticles plus Gemcitabine-Based Chemotherapy in Routine Clinical Practice*", was delivered by Dr Enrique Vázquez-Sequeiros from University Hospital Ramón y Cajal, Madrid, Spain, on behalf of the OSPREY Registry Investigators.

The OSPREY Registry is a post-market, multi-centre, observational and prospective registry evaluating the safety and effectiveness of OncoSil™ in real-world clinical settings. As of 1 August 2025, the OSPREY Registry had enrolled 64 patients across Austria, Greece, Italy and Spain, with total enrolment now exceeding 80 patients.

Key Interim Findings

The interim analysis demonstrated:

- Strong safety profile with adverse device effects (ADEs) reported in 15.6% of patients, consisting primarily of mild Grade 1 abdominal pain and one Grade 2 fatigue event. Importantly, there were:
  - No Grade ≥3 ADEs; and
  - No serious adverse device effects (SADEs).
- Encouraging efficacy outcomes, including:
  - Local Disease Control Rate at 12 weeks post-implant was 91.4% in patients receiving first-line chemotherapy and 77.8% in patients receiving second-line chemotherapy.
  - To date, 7 patients have undergone surgical resection with curative intent following treatment with OncoSil™, including 3 patients implanted within ≤4 months of commencing first-line chemotherapy, 3 patients implanted between 4–12 months after commencing first-line chemotherapy, and 1 patient implanted within ≤4 months of commencing second-line chemotherapy.
  - Of the 7 surgically resected patients, 5 patients (71.4%) achieved an R0 resection margin and 2 patients (28.6%) achieved an R1 resection margin.
- Median overall survival results included:
  - 20.6 months for patients implanted within ≤4 months of commencing first-line chemotherapy; and
  - 22.0 months for patients implanted between 4–12 months after commencing first-line chemotherapy.

The investigators concluded that the addition of EUS-guided implantation of OncoSil™ phosphorus-32 microparticles to gemcitabine-based chemotherapy in routine clinical practice for patients with LAPC was safe and well tolerated, with a limited number of anticipated ADEs experienced and no SADEs or Grade ≥3 ADEs reported. OncoSil™ appears to provide local disease control, downstaging to surgical resection in a proportion of patients and encouraging overall survival.

The interim findings from the OSPREY registry demonstrate a highly encouraging overall survival profile for patients with unresectable LAPC treated with the OncoSil™ device in routine clinical practice. Historically, prospective clinical trials evaluating first-line gemcitabine plus nab-paclitaxel alone in patients with unresectable LAPC have reported median overall survival ranging from 12.7 to 18.8 months.[1][2][3] In this context, the median overall survival of 20.6 and 22.0 months observed in first-line patients enrolled in the OSPREY registry represents a notable improvement over historical benchmark.

[1] Cascinu S, Berardi R, Bianco R et al. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial. Eur J Cancer. 2021 May;148:422-429. doi: 10.1016/j.ejca.2021.02.023.

[2] Babiker HM, Picozzi V, Chandana SR et al. Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase III PANOVA-3 study. J Clin Oncol 2025. doi:10.1200/JCO 25-00746.

[3] Philip P, Lacy J, Portales F et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 2020; 5: 285–94, doi: 10.1016/S2468-1253(19)30327-9.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"The presentation of the interim OSPREY Registry results at ESGE Days 2026 is another important milestone for OncoSil and provides further validation of the encouraging clinical outcomes previously observed in our earlier studies and clinical data. Importantly, these results demonstrate that the safety profile and efficacy outcomes associated with OncoSil™ can also be achieved in routine real-world clinical practice across multiple centres in Europe. Seeing consistent disease control, encouraging survival outcomes and downstaging to surgery in selected patients in a real-world setting further strengthens our confidence in the role OncoSil™ in the treatment of unresectable locally advanced pancreatic cancer."

Dr Enrique Vázquez-Sequeiros from University Hospital Ramón y Cajal, Madrid, Spain who presented the interim analysis at ESGE Days 2026, said:

"Presenting the first interim analysis of the OSPREY Registry at ESGE Days 2026 is an important milestone in demonstrating the real-world potential of the OncoSil™ Device for patients with unresectable locally advanced pancreatic cancer. These multicentre European data show that treatment with OncoSil™ alongside gemcitabine-based chemotherapy is safe, well tolerated, and associated with encouraging disease control, downstaging to surgery in selected patients, and promising overall survival outcomes. We believe these findings further support the role of OncoSil™ as a valuable addition to the treatment pathway for this highly challenging disease."

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 96424981	**Mr. Tim Luscombe** Company Secretary E: tim.luscombe@bio101.com T: +61 429 707 079

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year[1]. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. https://gco.iarc.fr/en

About ESGE Days

ESGE Days is a multi-day event providing an inspiring environment for the whole endoscopy community to interact, discuss, debate and learn about the latest advances in endoscopy. It has a cutting-edge scientific programme that brings together live demonstrations, a wide variety of session types, specialized symposia and hands-on training.